Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy.
about
Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasisContact inhibition of VEGF-induced proliferation requires vascular endothelial cadherin, beta-catenin, and the phosphatase DEP-1/CD148Integrin alphavbeta3, requirement for VEGFR2-mediated activation of SAPK2/p38 and for Hsp90-dependent phosphorylation of focal adhesion kinase in endothelial cells activated by VEGFContinuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicityBrivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibitionPathways for aberrant angiogenesis in pancreatic cancerRamucirumab in metastatic colorectal cancer: evidence to date and place in therapyClinical utility of ramucirumab in advanced gastric cancerTumour Angiogenesis and Angiogenic Inhibitors: A ReviewEvolution of ramucirumab in the treatment of cancer - A review of literatureAcetylbritannilactone Modulates Vascular Endothelial Growth Factor Signaling and Regulates Angiogenesis in Endothelial CellsRoles of the endogenous VEGF receptors flt-1 and flk-1 in astroglial and vascular remodeling after brain injuryVascular endothelial growth factor (VEGF)-driven actin-based motility is mediated by VEGFR2 and requires concerted activation of stress-activated protein kinase 2 (SAPK2/p38) and geldanamycin-sensitive phosphorylation of focal adhesion kinaseA humanized anti-VEGF rabbit monoclonal antibody inhibits angiogenesis and blocks tumor growth in xenograft modelsTargeting the vascular endothelial growth factor pathway in the treatment of human malignancy.Conditional HIF-1 induction produces multistage neovascularization with stage-specific sensitivity to VEGFR inhibitors and myeloid cell independence.Disruption of anthrax toxin binding with the use of human antibodies and competitive inhibitors.Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy.A vascular endothelial growth factor high affinity receptor 1-specific peptide with antiangiogenic activity identified using a phage display peptide library.Human combinatorial Fab library yielding specific and functional antibodies against the human fibroblast growth factor receptor 3.Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axisInhibition of lymphangiogenesis and lymphatic drainage via vascular endothelial growth factor receptor 3 blockade increases the severity of inflammation in a mouse model of chronic inflammatory arthritisEndothelial membrane remodeling is obligate for anti-angiogenic radiosensitization during tumor radiosurgery.Anticancer Role of PPARgamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes.Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.Pre-clinical longitudinal monitoring of hemodynamic response to anti-vascular chemotherapy by hybrid diffuse optics.Therapeutic potential of manipulating VEGF splice isoforms in oncologyAngiogenesis in epithelian ovarian cancer.Targeted inhibition of VEGF receptor 2: an update on ramucirumab.Vascular endothelial growth factor receptor 2-targeted chemoprevention of murine lung tumors.A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancerGene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in miceDifferential effects of VEGFR-1 and VEGFR-2 inhibition on tumor metastases based on host organ environmentMechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy.Rapid remodeling of airway vascular architecture at birth.Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in micePleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models.Clinical advances in the development of novel VEGFR2 inhibitors.Kinase insert domain-containing receptor kinase inhibitors as anti-angiogenic agents.Vascular endothelial growth factor blockade rapidly elicits alternative proangiogenic pathways in neuroblastoma
P2860
Q22305863-D7B8ADD6-2BF3-4679-A513-9F4FDEE27B98Q24303092-F9F14BFD-55FB-4B62-A4E1-B654EF03ADA9Q24306175-07702C16-F216-4CCC-913B-9ABC444A773FQ24561642-8966FB97-5FA1-44EC-A37F-2E0BA8759232Q24616631-DD851C9A-37FE-46CE-8221-13917688BD18Q24800215-E827C61D-BF09-452B-A025-08AB32BE77FBQ26745418-BDFC5CAF-99EE-4127-9549-DF28D3059FBBQ26785665-BD211002-473B-4E90-B8A2-50D46400E4AEQ26798822-5D59DBDC-5CCC-48EB-8452-E39A892884D6Q28276412-C52ABF8A-9AAF-4586-A183-48FCE676A0B3Q28550070-E808CCCE-9121-4166-A6C4-7E170DC9F816Q28575249-602D93C2-34E8-4E17-8C26-6C27FAA0CD7BQ28646403-4E23EA9B-1E46-4F1C-97BB-DBD88DC459F0Q28749085-35FBF92D-D9EE-4D5E-AD82-BDE31C8988B5Q30358961-DB9F0D58-18E1-4BD9-AD3F-531A4FD2127FQ30468545-BCCBA70D-4BB4-40FE-9A7F-41B13ACEB339Q30638627-07C046F1-B36C-45AE-80BE-831BC120BAABQ30790872-03F9B2E4-F1DA-4E91-B536-7B3136B716A2Q30979922-9B855CE8-59C0-456D-AB15-28C8C44A3B15Q31148688-55A60094-0D48-4BF8-B6E8-46A8CFE154A8Q33565805-0BA374B6-9398-42A8-A813-998A01334D4EQ33606922-A6156402-0574-45AE-8101-C0A35960B717Q33680346-D3BA8BFD-DBD8-44F9-8B42-8F4D98E621E9Q33692555-643FADD8-D444-46E2-8343-2C854DA100ABQ33710574-DE9A1105-FAD4-4C0B-9C6A-E2518CB3CFB7Q33824587-65545CD2-7139-4B4A-907B-40CBBAD532F4Q33888458-2A880285-1F99-4288-A75A-0A537B86D37BQ33919078-1C220AEE-D090-4D5A-8C2D-C725F7C67D28Q34040956-F22E7F51-A61A-42FF-9564-5ACE2BB0FD16Q34103766-A7CF8DB9-13AD-4CDD-A6B1-A70AAD9766DBQ34194044-A7C65427-A4F5-44BE-9406-03172E840A1FQ34245416-1CA35645-56BE-4DAD-811C-378FC6E37D94Q34268230-34265092-31BB-44FB-B471-ECA7F70A3EE9Q34347733-3497E5EE-8CFE-49CF-8094-DC714EF73C32Q34383197-034C9D01-A183-44CF-95EF-DEE82596C2D6Q34432972-21B2C511-0848-4D1D-8E73-036729FBD475Q34497997-A3AD738A-410A-4510-BC90-D77523686E41Q34658366-5AF2373B-F141-4E08-A1CE-202B045FD096Q34660821-EA687FFC-9C91-459E-8B32-FA39F21E8DB6Q34759474-A536BB58-B590-4CEF-B995-2DC6962816D1
P2860
Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy.
description
1998 nî lūn-bûn
@nan
1998 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Monoclonal antibodies targetin ...... giogenic therapeutic strategy.
@ast
Monoclonal antibodies targetin ...... giogenic therapeutic strategy.
@en
type
label
Monoclonal antibodies targetin ...... giogenic therapeutic strategy.
@ast
Monoclonal antibodies targetin ...... giogenic therapeutic strategy.
@en
prefLabel
Monoclonal antibodies targetin ...... giogenic therapeutic strategy.
@ast
Monoclonal antibodies targetin ...... giogenic therapeutic strategy.
@en
P2093
P356
P1476
Monoclonal antibodies targetin ...... giogenic therapeutic strategy.
@en
P2093
Hicklin DJ
Kotanides H
Pytowski B
Rockwell P
P2888
P304
P356
10.1023/A:1006094117427
P577
1998-06-01T00:00:00Z
P6179
1050230898